Clinical Trials Browser

Phase 2 × Neuritis × acalabrutinib × Clear all

NCT05065554 2025-12-05

ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

Phase 2 Active not recruiting

Waldenstrom Macroglobulinemia, Neuritis